CD19 and B-cell non-Hodgkin lymphoma: Here, we report the effectiveness and safety of our clinical study using 4th-generation CAR-T cells featuring an anti-CD19 CAR and the iCasp9 gene in patients with R/R B cell NHL and evaluated the risk factors affecting response rate and survival.